Seres Therapeutics
215 First Street
Cambridge
Massachusetts
02142
United States
Tel: 617-945-9626
Website: http://serestherapeutics.com/
Email: info@sereshealth.com
269 articles about Seres Therapeutics
-
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
8/6/2019
Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs
-
Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
8/6/2019
Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.
-
Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
8/1/2019
Seres Therapeutics, Inc. announced that it will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET.
-
Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019
8/1/2019
Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on August 6, 2019 at 8:00 a.m. ET to discuss second quarter 2019 results and provide a general business update.
-
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
6/19/2019
FDA alert does not impact Seres’ microbiome investigational therapeutic candidates
-
Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock - June 14, 2019
6/14/2019
Seres Therapeutics, Inc. announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock, at a public offering price of $2.25 per share, before underwriting discounts and commissions.
-
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
6/12/2019
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock.
-
Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
5/29/2019
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY on Wednesday, June 5th at 2:30 p.m. ET.
-
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
5/2/2019
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) today reported first quarter 2019 financial results and provided business updates.
-
Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
4/29/2019
Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019 results and provide a general business update.
-
The two companies will focus on utilizing the microbiome, all the bacteria, viruses and fungi in the body, to improve cancer immunotherapy.
-
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
3/11/2019
Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer
-
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
3/6/2019
Seres Therapeutics, Inc reported fourth quarter and full year 2018 financial results and provided an operational update.
-
Seres Therapeutics to Present at Three Upcoming March Conferences
3/5/2019
Seres Therapeutics, Inc. announced that it will present at each of the following upcoming healthcare conferences
-
Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
3/4/2019
Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
-
BioSpace Movers and Shakers: Feb. 8
2/8/2019
In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles. -
Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
2/7/2019
Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study
-
Seres Therapeutics Announces Chief Executive Officer Transition
1/15/2019
Eric Shaff, previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer
-
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
1/3/2019
Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA)
-
Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
11/9/2018
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.